Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.
Earnings and Valuation
This table compares Lucid Diagnostics and IDEXX Laboratories”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Lucid Diagnostics | $4.36 million | 36.43 | -$45.53 million | ($1.19) | -1.00 |
IDEXX Laboratories | $3.90 billion | 13.07 | $887.87 million | $12.01 | 53.03 |
Institutional & Insider Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 1.0% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Lucid Diagnostics and IDEXX Laboratories, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Lucid Diagnostics | 1 | 0 | 5 | 0 | 2.67 |
IDEXX Laboratories | 0 | 4 | 7 | 1 | 2.75 |
Lucid Diagnostics currently has a consensus target price of $3.70, indicating a potential upside of 210.92%. IDEXX Laboratories has a consensus target price of $656.50, indicating a potential upside of 3.08%. Given Lucid Diagnostics’ higher possible upside, equities analysts plainly believe Lucid Diagnostics is more favorable than IDEXX Laboratories.
Risk and Volatility
Lucid Diagnostics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
Profitability
This table compares Lucid Diagnostics and IDEXX Laboratories’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Lucid Diagnostics | -1,476.35% | N/A | -120.43% |
IDEXX Laboratories | 24.41% | 64.42% | 29.89% |
Summary
IDEXX Laboratories beats Lucid Diagnostics on 12 of the 15 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.